No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SPRO Spero Therapeutics
- 1.400
- -0.070-4.76%
Close Apr 19 16:00 ET
- 1.440
- +0.040+2.86%
Post 16:04 ET
75.45MMarket Cap3.26P/E (TTM)
1.540High1.400Low378.24KVolume1.480Open1.470Pre Close546.65KTurnover1.01%Turnover Ratio3.26P/E (Static)53.89MShares1.99552wk High0.71P/B52.43MFloat Cap0.99052wk Low--Dividend TTM37.45MShs Float23.639Historical High--Div YieldTTM9.52%Amplitude0.680Historical Low1.445Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Cantor Fitzgerald Reiterates Overweight on Spero Therapeutics
Express News | HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target
Spero Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/18/2024 300% HC Wainwright & Co. → $7 Reiterates Buy → Buy 11/14/2023 300% HC Wainwright & Co. → $7 Rei
Spero Therapeutics' Robust Drug Pipeline and Positive Trial Advancements Prompt Buy Rating
Spero Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Spero Therapeutics Files $300M Mixed Securities Shelf
Comments
Investment Bank Reiterates 'Buy' Rating For Therapeutics Company
Spero Therapeutics: A Biotech Investment Opportunity That You Shouldn't Miss.
In the ever-evolving world of biotechnology, one company that has recently caught the attention of investors and industry analysts alike is Spero Therapeutics (NASDAQ: $SPRO). HC Wainwright & Co., a reputable full-service investment bank, has reiterated its 'Buy' rating on the company's stock and maintained a price target of $7. This not only indicates the...
In the ever-evolving world of biotechnology, one company that has recently caught the attention of investors and industry analysts alike is Spero Therapeutics (NASDAQ: $SPRO). HC Wainwright & Co., a reputable full-service investment bank, has reiterated its 'Buy' rating on the company's stock and maintained a price target of $7. This not only indicates the...
Spero Therapeutics' P/S lags behind the industry despite a strong price move. Its forecast for shrinking revenue and poor outlook justify the low P/S ratio. These conditions form a barrier for the share price at these levels.
1
Ankit Mahadevia's recent sale below the current price of US$1.45 is seen as discouraging, suggesting satisfaction with a lower valuation. The lack of insider purchases over the last year and low level of insider ownership compared to most companies raises caution for potential investors.
1
Support at $2.18
$Spero Therapeutics(SPRO.US$ seems to be holding at $2.18 support, can start to move up now.
2
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg